9887 — Nanjing Leads Biolabs Co Income Statement
0.000.00%
Last trade - 00:00- HK$13.08bn
- HK$12.82bn
Annual income statement for Nanjing Leads Biolabs Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS |
| Status: | Final | Final |
| Revenue | ||
| Total Revenue | 8.87 | 0 |
| Cost of Revenue | ||
| Gross Profit | 5.68 | 0 |
| Research And Development | ||
| Unusual Expense / Income | ||
| Other Operating Expenses | ||
| Total Operating Expenses | 370 | 295 |
| Operating Profit | -361 | -295 |
| Total Net Non Operating Interest Income / Expense | ||
| Net Income Before Taxes | -362 | -301 |
| Provision for Income Taxes | ||
| Net Income After Taxes | -362 | -301 |
| Net Income Before Extraordinary Items | ||
| Net Income | -362 | -301 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | -362 | -301 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | -1.72 | -1.13 |